Streetbeat News

Products Services

IKT

Inhibikase Therapeutics has released an analysis of eleven unblinded participants from the 201 trial evaluating Risvodetinib (IKT-148009) in untreated Parkinson's disease.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:09 am

TLSA

Tiziana Life Sciences has reported six-month data showing clinical improvements in non-active secondary progressive multiple sclerosis patients treated with Foralumab. The improvements were related to Modified Fatigue Impact Scale scores and similar clinical measures of physical function.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 11:02 am

BNOX

Bionomics has announced the outcomes of an end-of-phase 2 meeting with the FDA for BNC210, a drug for the acute treatment of social anxiety disorder. The company plans to move into phase 3 studies, with the first patient dosing planned for Q1 FY24.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:55 am

MRK

The European Commission has approved Merck's KEYTRUDA as a treatment for adults with non-small cell lung cancer at high risk of recurrence. This follows a positive recommendation from the Committee for Medicinal Products for Human Use and is based on results from the Phase 3 KEYNOTE-091 trial.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:47 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) is set to release its Q3 results, with concerns over further margin erosion. However, retail investors seem more focused on the number of Cybertrucks Tesla plans to deliver in 2024 and the availability of the Model 3 refresh in the U.S. Tesla's auto gross margin has been declining for the past three quarters, but analysts have high hopes for the Cybertruck, which could boost the company's overall volume in 2024. Tesla's stock slipped 0.85% in premarket trading.

Portfolio Pulse from Shanthi Rexaline

October 16, 2023 | 10:42 am

AAPL

FXI

A recent study shows that sales of Apple's iPhones in China have had a disappointing start, with sales down 4.5%. This comes as Huawei's market share in the region continues to rise.

Portfolio Pulse from Charles Gross

October 16, 2023 | 10:37 am

KIND

Nextdoor (NYSE:KIND), the neighborhood network, has announced the launch of several new solutions to maximize Ad performance, both online and offline. These new tools will allow advertisers to reach and activate neighbors on Nextdoor more effectively.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:33 am

KKR

KKR & Co Inc and Flerie have formed a new global pharma services platform, Frontier Biosolutions, which will invest in companies focused on specialized pharmaceutical services. As an initial investment, the platform has invested in Munich-based Coriolis Pharma, a company involved in formulation research and development, analytical services, and non-GMP manufacturing of biologics and cell and gene therapy products. The investment is expected to drive Coriolis' expansion strategy in the cell and gene therapy segment and boost its range of global services.

Portfolio Pulse from Lekha Gupta

October 16, 2023 | 10:23 am

IDYA

Ideaya Biosciences has initiated a Phase 2 expansion of the Darovasertib and Crizotinib combination in GNAQ/11 metastatic cutaneous melanoma.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:12 am

BGNE

Beigene has announced the presentation of new data highlighting the effectiveness of Tislelizumab plus chemotherapy combination strategy in solid tumors at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:09 am